Premium
O3‐02‐02: TREATMENT INITIATION CHARACTERISTICS OF ANTI‐DEMENTIA DRUG THERAPIES IN THE UNITED KINGDOM: A POPULATION‐BASED INCEPTION COHORT
Author(s) -
Andersen Kathleen M.,
Filion Kristian B.,
Kröger Edeltraut,
Champoux Nathalie,
Reynier Pauline,
Wilchesky Machelle
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2777
Subject(s) - medicine , galantamine , rivastigmine , memantine , donepezil , dementia , cohort , medical prescription , pediatrics , population , retrospective cohort study , disease , pharmacology , environmental health
Figure 1. Dist strategy, overa Date cut-point Excellence (N respectively], itor access. Female, n (%) 58,342 (64%) Age at MND diagnosis, mean (standard deviation) 83(7) CHARACTERISTICS OFANTI-DEMENTIA DRUG THERAPIES IN THE UNITED KINGDOM: A POPULATION-BASED INCEPTION COHORT Year of MND diagnosis by 5-year periods, n (%) 1997-2001 9,555 (11%) 2002-2006 21,016 (23%) 2007-2011 29,443 (32%) 2012-2017 31,911 (34%) Year of MND diagnosis, by NICE guideline period 1997-2005 30,743 (34%) 2006-2011 24,639 (27%) 2011-2017 35,643 (39%) Smoking status, n (%) Ever 24,701 (27%) Never 19,774 (22%) Unknown 46,550 (51%) Alcohol-related disorder in prior year, n (%) 1,063 (1%) Body Mass Index (kg/m), n (%) Underweight (< 18.5) 4,074 (4%) Normal (18.5–24.9) 29,042 (32%) Overweight (25.0-29.9) 19,991 (22%) Obese (>30) 9,282 (10%) Unknown 28,636 (31%) MND sub-type, n (%) Alzheimer’s 51,230 (56%) Vascular dementia 20,656 (23%) Non-specific dementia 16,766 (18%) Other 2,373 (3%) Indicators of dementia severity in year prior to diagnosis, n (%) Urinary & faecal incontinence 4,582 (5%) Kathleen M. Andersen, Kristian B. Filion, Edeltraut Kr€oger, Nathalie Champoux, Pauline Reynier, Machelle Wilchesky, McGill University, Montreal, QC, Canada; Universit e Laval, Quebec City, QC, Canada; Universit e de Montr eal, Montreal, QC, Canada; Lady Davis Institute, Montreal, QC, Canada. Contact e-mail: kathleen.andersen@mail. mcgill.ca